According to Integra LifeSciences's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 18.1639. At the end of 2022 the company had a P/E ratio of 26.0.
Year | P/E ratio | Change |
---|---|---|
2022 | 26.0 | -22.66% |
2021 | 33.6 | -17.84% |
2020 | 40.9 | -58.75% |
2019 | 99.0 | 59.36% |
2018 | 62.2 | 8.54% |
2017 | 57.3 | 33.23% |
2016 | 43.0 | -102.97% |
2015 | < -1000 | -2888.61% |
2014 | 52.0 | -173.44% |
2013 | -70.7 | -366.29% |
2012 | 26.6 | -16.41% |
2011 | 31.8 | 49.17% |
2010 | 21.3 | 0.55% |
2009 | 21.2 | -40.43% |
2008 | 35.6 | 2.65% |
2007 | 34.7 | -18.64% |
2006 | 42.6 | 47.73% |
2005 | 28.8 | -55.5% |
2004 | 64.8 | 107.98% |
2003 | 31.2 | 113.56% |
2002 | 14.6 | -40.74% |
2001 | 24.6 |
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.